Clearside Biomedical Inc reports results for the quarter ended June 30 - Earnings Summary

• Clearside Biomedical Inc CLSD.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of seven analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -7 cents per share.

• Revenue rose 446.7% to $492.00 thousand from a year ago; analysts expected $170.00 thousand.

• Clearside Biomedical Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $4.5 million.

• Clearside Biomedical Inc shares had fallen by 49.6% this quarter and lost 57.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Clearside Biomedical Inc is $5.00, about 91.9% above its last closing price of $0.40

This summary was machine generated from LSEG data August 12 at 02:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)